Down-regulation of FOS-like antigen 1 enhances drug sensitivity in breast cancer.

OBJECTIVE Multidrug resistance (MDR) to chemotherapeutic drugs is an important reason for clinical chemotherapy failure. So far, the relationship between FOS-like antigen1 (FOSL1) and chemotherapy sensitivity of breast cancer remains unclear. This study investigates the relationship between FOSL1 and chemotherapy sensitivity of breast cancer and its molecular mechanism. METHODS Doxorubicin-resistant MCF-7/ADR breast cancer cells were transfected with NC (control) or FOSL1 siRNA and assayed for cell viability and relative colony number by MTT assay and colony formation, respectively. The expression level of FOSL1 was detected by immunohistochemistry (IHC). The relationship between FOSL1 and chemotherapy sensitivity was analyzed by a one-way of variance analysis and Pearson's chi-square test among a total of 50 patients with stage II and III breast cancer before and after they received epirubicin-based neoadjuvant chemotherapy (NCT) between 2012 and 2017. RESULTS The expression of FOSL1 was increased in breast cancer tissues compared with normal breast tissues (P<0.05), and the expression of FOSL1 was decreased after NCT treatment compared with breast cancer tissues (or before NCT). This lower expression of FOSL1 was correlated with chemotherapy resistance or chemotherapy sensitivity (P<0.05). Moreover, the expression level of FOSL1 was markedly lower in NCT-sensitive patients than that of NCT-resistant patients (P<0.05). CONCLUSION Down-regulation of FOSL1 potentiated chemotherapy sensitivity of breast cancer, and its lower expression attenuated chemotherapeutic drug resistance in human breast cancer cells. FOSL1 might be a drug target for predicting chemotherapy effect in breast cancer.

[1]  Sung-Bae Kim,et al.  Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  D. Berry,et al.  Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. , 2020, JAMA oncology.

[3]  Min Zhao,et al.  MicroRNA-130a reduces drug resistance in breast cancer. , 2019, International journal of clinical and experimental pathology.

[4]  P. He,et al.  FOSL1 enhances growth and metastasis of human prostate cancer cells through epithelial mesenchymal transition pathway. , 2018, European review for medical and pharmacological sciences.

[5]  Xiaowei Chen,et al.  microRNA‐130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO‐1 , 2018, Journal of cellular biochemistry.

[6]  Tao Zhang,et al.  Down-regulation of RIP3 potentiates cisplatin chemoresistance by triggering HSP90-ERK pathway mediated DNA repair in esophageal squamous cell carcinoma. , 2018, Cancer letters.

[7]  E. Wardelmann,et al.  Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment , 2018, PloS one.

[8]  Min Zhao,et al.  Expression of and correlation between BCL6 and ZEB family members in patients with breast cancer , 2017, Experimental and therapeutic medicine.

[9]  R. Mckinnon,et al.  Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model , 2017, Breast Cancer Research and Treatment.

[10]  P. Khatri,et al.  An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer , 2017, Nature Communications.

[11]  Wenfang Li,et al.  Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis , 2017, Molecular medicine reports.

[12]  S. Masood.  Neoadjuvant chemotherapy in breast cancers , 2016, Women's health.

[13]  Chun-Woong Park,et al.  Hepatic uptake of epirubicin by isolated rat hepatocytes and its biliary excretion after intravenous infusion in rats , 2014, Archives of pharmacal research.

[14]  S. Oliviero,et al.  Role of the AP-1 transcription factor FOSL1 in endothelial cells adhesion and migration , 2013, Cell adhesion & migration.

[15]  Min Zhao,et al.  Expression and correlation of Twist and gelatinases in breast cancer , 2013, Experimental and therapeutic medicine.

[16]  D. Stupack,et al.  Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy. , 2012, Cancer research.

[17]  U. Gunnarsson,et al.  Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  N. Sarvilinna,et al.  Inhibition of FOSL1 overexpression in antiestrogen-resistant MCF-7 cells decreases cell growth and increases vacuolization and cell death , 2011, Steroids.

[19]  C. Wittekind,et al.  [TNM classification of malignant tumors 2010: General aspects and amendments in the general section]. , 2010, Der Pathologe.

[20]  J. Soares,et al.  BCL-6 Oncoprotein in Breast Cancer: Loss of Expression in Disease Progression , 2009, Pathobiology.

[21]  J. Nitiss.  Targeting DNA topoisomerase II in cancer chemotherapy , 2009, Nature Reviews Cancer.

[22]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[23]  N. Magné,et al.  Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen , 2005, Supportive Care in Cancer.

[24]  K. Belguise,et al.  FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells , 2005, Oncogene.

[25]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[26]  P. Vogt.  Fortuitous convergences: the beginnings of JUN , 2002, Nature Reviews Cancer.

[27]  P. Polakis,et al.  Activation of the Wnt Pathway Interferes with Serum Response Element-driven Transcription of Immediate Early Genes* , 2002, The Journal of Biological Chemistry.

[28]  W. Böcker.  [WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics]. , 2002, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[29]  E. Tulchinsky,et al.  Fos family members: regulation, structure and role in oncogenic transformation. , 2000, Histology and histopathology.

[30]  R. Demicheli,et al.  Drugs ten years later: epirubicin. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[32]  R. J. Cersosimo,et al.  Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.